Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Let's Make a Deal: Levin's Ovid Raises $75m

This article was originally published in Scrip

Executive Summary

Former Teva Pharmaceutical Industries president and CEO Jeremy Levin has gone back to his dealmaking roots as chairman and CEO of Ovid Therapeutics, which just closed a $75m Series B funding round to fund development and acquisition of treatments for rare neurological diseases.

You may also be interested in...



The New Revolutionary: Ovid's Levin On Pioneering In Neurology

Emerging Company Profile: Orphan disease-focused Ovid Therapeutics, with $80m in VC financing in the bag and an alliance with Takeda, recently raised $75m in a US initial public offering. Scrip spoke with CEO Jeremy Levin and chief business and finance officer Yaron Werber before the recent IPO about how the young biotech firm intends to become a successful neurology company.

After Tocagen Thaws IPO Freeze, Verona And Zymeworks Bring April Total To Three

With three biopharma initial public offerings in April, the second quarter is on track to beat the first quarter's total of five IPOs – three in January and two in March – and several more are in the queue.

Finance Watch: Venture Capital Drives Record-Breaking Year For Cell And Gene Therapies

Private Company Edition: Recent VC financings across biopharma sectors include three major mega-rounds as Generate Biomedicines bringing in $370m, followed by $250m for Acelyrin and $125m for Chroma Medicine. Also, Treadwell raised a $91m series B and Ncardia brought in $60m-plus.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029477

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel